All but left for dead at $0.84 per share back in March, Immunomedics
That mouthwatering six-month return may have gotten Immunomedics (back) on your radar screen, but I'd recommend treading lightly, Fools. Lupus is where drugs go to die, and epratuzumab is a drug that has already died a few times and come back to life.
Sure, epratuzumab could follow in the footsteps of Benlysta, from GlaxoSmithKline
Then again, epratuzumab seems to be an unkillable zombie, so maybe it would be right at home in the graveyard. In 2004, Amgen
If you've got a high risk tolerance, Immunomedics might be a reasonable bet still at this point -- it's down about 12% today. Its market cap is a fifth of Human Genome Sciences', which is also developing a lupus drug, so there's still plenty of upside, if the phase 3 trial is successful.
But that's still a big if.